Gilead Sciences, Inc. (GILD)
| Market Cap | 120.55B |
| Revenue (ttm) | 28.74B |
| Net Income (ttm) | 5.97B |
| Shares Out | 1.24B |
| EPS (ttm) | 4.73 |
| PE Ratio | 20.49 |
| Forward PE | 11.92 |
| Dividend | $3.16 (3.26%) |
| Ex-Dividend Date | Jun 13, 2025 |
| Volume | 13,140,336 |
| Open | 98.07 |
| Previous Close | 98.16 |
| Day's Range | 96.20 - 98.65 |
| 52-Week Range | 62.07 - 119.96 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 109.00 (+12.48%) |
| Earnings Date | Apr 24, 2025 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $109.0, which is an increase of 12.48% from the latest price.
News
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Gilead announces $11 billion in new investments in US
Gilead Sciences on Wednesday announced $11 billion in capital and operational investments in the U.S. to supplement an already planned spending of $21 billion in domestic manufacturing and R&D through...
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with ch...
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the Europe...
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Ca...
Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors
Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying kickbacks to doctors who agreed to prescribe its HIV drugs, the U.S. attorney's of...
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, May 7-10,...
Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks
As tariffs loom over the sector, biotechs with U.S.-based manufacturing and intellectual property are soothing investor concerns.
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance
Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest perfor...
AAPL Doubling India iPhone Production, TMUS Sells, GILD Healthcare Headwinds
Apple (AAPL) is expected to double its iPhone output from India to 80 million. Diane King Hall says the company is bracing to maneuver its production around tariffs aimed at China.
Skechers Posts Weak Revenue, Joins Intel, Gilead Sciences And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Friday.
Gilead Sciences, Inc. (GILD) Q1 2025 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Ch...
Gilead reports quarterly profit, revenue flat as cancer sales slow
Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of drugs for HIV and liver disease along with expense tightening offset lower can...
Gilead Sciences Announces First Quarter 2025 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations. “Gilead had a strong start to the year driven by ex...
Stocks on the Move: Merck, Gilead Sciences, P&G, PG&E Corp, Adobe and the URNM
The Investment Committee debate how to trade some stocks on the move today.
Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type
Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an agg...
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzu...
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Top 3 Nasdaq 100 stocks rising as it moves into a correction
The Nasdaq 100 Index has slumped into a technical correction this year, falling by over 16% from its highest level in January. It has crashed to a low of $18,520, its lowest level since August 9 of la...
Final Trades: Gilead Sciences, Amazon, Alphabet and KLA Corp.
The Investment Committee give you their top stocks to watch for the second half.
Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)
We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable income strategy for Opti...